Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Pfizer’s Dalbavancin “Approvable”

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

FDA issued an "approvable" letter for Pfizer's lipoglycopeptide antibiotic dalbavancin Sept. 21, the agency said

You may also be interested in...



Pfizer Receives “Approvable” Letter For MRSA Antibiotic Dalbavancin

Broad range of issues - from trial design to manufacturing - must be addressed before firm can add product to its antibiotic portfolio.

Pfizer Receives “Approvable” Letter For MRSA Antibiotic Dalbavancin

Broad range of issues - from trial design to manufacturing - must be addressed before firm can add product to its antibiotic portfolio.

Pfizer “Approvable” Streak Continues With Second letter For Anidulafungin

The antifungal agent’s second approvable letter is for an esophageal candidiasis indication.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By